AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06702566
Drug: Targeted drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted drugs includes EGFR-TKIs,ALK-TKIs,Multitargeted Tyrosine Kinase Inhibitors, VEGF antibody, EGFR antibody, antibody-drug conjugates drugs
Trial: NCT04590417
Drug: Estradiol valerate 2 mg, cyproterone acetate 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The entire study period will be approximately 1 year, which will include around 2 months of document preparation, 5 months of recruitment, 3 months of follow-up, and 2 months of data analysis.
Trial: NCT04851093
Drug: TCM granule plus conventional drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive conventional drug according to 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Medicine Diagnosis Treatment Guidelines.~Yiqiwenfei granule for qi deficiency and internal cold fluid syndrome.~Fuzhengqinghua granule for qi and yin deficiency and unclean phlegm heat syndrome.~Fuzhengzaohua granule for lung and spleen qi deficiency and phlegm-damp amassing in lung syndrome.~TCM granule (Jiangyin Tian Jiang Pharmaceutical Co.,Ltd, 10g/packet) will be administered twice daily for 8 weeks.
Trial: NCT04851093
Drug: TCM placebo granule plus conventional drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive conventional drug according to 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Medicine Diagnosis Treatment Guidelines.~Placebo Yiqiwenfei granule for qi deficiency and internal cold fluid syndrome.~Placebo Fuzhengqinghua granule for qi and yin deficiency and unclean phlegm heat syndrome.~Placebo Fuzhengzaohua granule for lung and spleen qi deficiency and phlegm-damp amassing in lung syndrome.~TCM placebo granule (Jiangyin Tian Jiang Pharmaceutical Co.,Ltd, 10g/packet) will be administered twice daily for 8 weeks.~The appearance, weight, color and odor of the preparation are the same as those of experimental group.~The placebo granule consists of dextrin, bitter and 5% of the TCM granule.
Trial: NCT06064006
Drug: NNC0487-0111
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNC0487-0111 will be administered as a subcutaneous (s.c. under the skin) injection.
Trial: NCT06064006
Drug: Placebo (NNC0487-0111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching NNC0487-0111 will be administered as a subcutaneous (s.c. under the skin) injection.
Trial: NCT05341583
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 225 mg once daily until disease recurrence or up to 2 years, whichever occurs earlier.
Trial: NCT05565105
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide: 60 mg/kg/day x 2 or Fludarabine 25 mg/m\^2 x 5 if cyclophosphamide is contraindicated
Trial: NCT05309655
Drug: Adenosine Stress Cardiac Magnetic Resonance Imaging
RxNorm normalized name: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine stress CMR test with contrast to include cardiovascular structural and functional measures including myocardial blood flow through quantitative perfusion mapping. Participants will have 3 stress tests as a part of this research. These tests will happen when at the beginning of the study, and then every year for 2 years.
Trial: NCT06308874
Drug: Bmg dose administration group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally, Bmg tablet single administration
Trial: NCT06308874
Drug: Bmg dose administration group- Placebo
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally, Placebo Bmg tablet single administration
Trial: NCT05098275
Drug: DA-5210 10/500mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose administration (one tablet once a day)
Trial: NCT05098275
Drug: DA-5210-R 10/500mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose administration (one tablet once a day)
Trial: NCT05225831
Drug: Cyclophosphamide,Fludarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given
Trial: NCT05347147
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is supplied as 2 parts (visually identical to the Presendin vial and pre-filled diluent syringe). The drug part will exclude the active pharmaceutical ingredient (exenatide acetate) and the diluent part will be the same as the active treatment diluent. The drug part is suspended in the diluent part solution and administered SC as a suspension.
Trial: NCT05658107
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05926492
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1) High-dose methotrexate : 8-12 g/m2 (MTX chemotherapy requires blood drug concentration monitoring), day 1 and 8; 2) Doxorubicin 60 mg/m2 or liposomal doxorubicin 45mg/ m2, day 17; 3) Cisplatin: 100 mg/m2, day 15;4) Ifosfamide; 2.5 g/m2, day 8-12.~The above drugs were used in turn, and 30 days were regarded as a treatment cycle.
Trial: NCT05380882
Drug: TQB2930 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2930 is an anti-HER2 bispecific antibody.
Trial: NCT05260541
Drug: 60 mg PRAX-114 or 40 mg PRAX-114
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral treatment for 4 weeks
Trial: NCT05260541
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral treatment for 4 weeks
Trial: NCT05260541
Drug: 40 mg PRAX-114
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral treatment for 8 weeks
Trial: NCT05943158
Drug: myoinositol and folic acid
RxNorm normalized name: ferrous fumarate and folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The pregnant women were given myoinositol+folic acid starting from initial examination of pregnancy until 24-28 weeks of gestation (time of oral glucose tolerance test)
Trial: NCT05943158
Drug: folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The pregnant women were given only folic acid starting from initial examination of pregnancy until 24-28 weeks of gestation (time of oral glucose tolerance test)
Trial: NCT05960708
Drug: YH35324
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of YH35324
Trial: NCT05960708
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of None of active ingredient
Trial: NCT05020730
Drug: PTM-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTM-001 (400 mg) every day for 12 weeks
Trial: NCT05448651
Drug: UPB-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT05448651
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT05149807
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Tegafur Gimeracil Oteracil Potassium Oxaliplatin
Trial: NCT04626141
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be dispensed as a 30-day supply of disposable pen injections.
Trial: NCT06298344
Drug: Thiamine
RxNorm normalized name: Thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily Thiamine 100 mg in 28 days
Trial: NCT06312761
Drug: Testosterone Undecanoate 237 MG Oral Capsule
RxNorm normalized name: testosterone undecanoate 237 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone Undecanoate 237 MG Oral Capsule
Trial: NCT06181045
Drug: LY3410738
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT06181045
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT06516445
Drug: CAPEOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine: 1000 mg/m2, BID, PO，D1-14, Q3W, C1-C4； Oxaliplatin: 130mg/m2, D1, ivgtt, 0-2h，Q3W，C1-4
Trial: NCT05073094
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equivalent volume of placebo (saline) as a bolus before aortic cross-clamping and in the cardioplegic solution
Trial: NCT05037409
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT05036473
Drug: WD-1603 Carbidopa-Levodopa Extended-Release Tablets
RxNorm normalized name: carbidopa / levodopa Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taking WD-1603 tablets or placebo orally three times a day, in the morning before meals, and the second and third medications will be taken after meals, once every 5 hours (±30 minutes).
Trial: NCT05036473
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets-matching the active groups.
Trial: NCT05123040
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 1 (starting dose) = 1 mg/kg~* Dose level 2 = 0.5 mg/kg~* Dose level 3 = 0.25 mg/kg~* Dose level 4 = 0.1 mg/kg~* Dose level 5 = 0 mg/kg~  • If dose level 1 is determined to be below the Recommended Phase 2 Dose (RP2D), the dose will be escalated:~* Dose level -1 = 1.5 mg/kg~* Dose level -2 = 2 mg/kg
Trial: NCT06528691
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenous (IV)
Trial: NCT04980391
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of placebo, administered intramuscularly in the non-dominant arm, at Day 1.
Trial: NCT06373978
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50mg every 8hours as needed for pain
Trial: NCT06702098
Drug: iNK cells
RxNorm normalized name: cuttle fish ink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induced pluripotent stem cells derived NK cells.
Trial: NCT04828083
Drug: Saline IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline of 1.5 mg/kg bolus followed by a 1.5 mg/kg/h infusion continuing to the end of phase 1 of post anesthesia care unit
Trial: NCT06703788
Drug: A fiixed combination of Chinese herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a fixed combination of Chinese herbal medicine with Ma-Xing-Gang-Shi-Tang (initiate at 2 grams, with increments of 0.5 grams every 2-4 weeks, up to a maximum dose of 4 grams once daily) and Coptis chinensis (initiate at 0.5 grams, with increments of 0.5 grams every 2-4 weeks, up to a maximum dose of 1 gram once daily), twice a day
Trial: NCT06499285
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneously every 4 weeks
Trial: NCT04762901
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT04762901
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT05761756
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of caffeine
Trial: NCT05110144
Drug: Placebo 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg tablet with no active study ingredient for 4 weeks
Trial: NCT05110144
Drug: Placebo 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60mg tablet with no active study ingredient for 4 weeks
Trial: NCT06290063
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo arm; capsules produced by Ecofibre/Ananda Hemp will be used
Trial: NCT05234619
Drug: Group one ( lidocaine or control LE ) Early deflation
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This will be conducted on 20 trauma patients group one who will be present for both elective and emergency Hand and Forearm surgery After establishing noninvasive arterial blood pressure, ECG, peripheral oxygen saturation monitoring, two venous cannulae will be inserted: one in a vein in the dorsum of operative hand and the other in the opposite hand for crystalloid infusion.~The opposite arm will be elevated for 2 minutes, and using an Esmarch bandage, the venous capacitance of the arm will be emptied. Then, a double-pneumatic tourniquet will be applied. The proximal tourniquet will be inflated to a pressure of 250 mmHg and circulatory isolation of the arm will be confirmed by inspection, lack of radial pulse and failure of pulse oximetry tracing of ipsilateral index finger then Esmarch bandage will be released then induction of lidocaine for intravenous regional anesthesia ( Bier block ) and Early deflation of distal tourniquet occurs after 20 minutes of IVRA induction
Trial: NCT05234619
Drug: Group two ( lidocaine , ketorolac LKE ) Early deflation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As the first intervention this will be conducted on group two but ketorolac will be combined with lidocaine in intravenous regional anesthesia
Trial: NCT05234619
Drug: Group four ( lidocaine , ketorolac LKL ) Late deflation
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As the first intervention this will be conducted on group four but late deflation of distal tourniquet in intravenous regional anesthesia after 40 minutes of induction of lidocaine and ketorolac for IVRA .
Trial: NCT06799000
Drug: Placebo 1
RxNorm normalized name: placebo 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to remibrutinib Dose A (oral)
Trial: NCT06799000
Drug: Placebo 2
RxNorm normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to remibrutinib Dose B (oral)
Trial: NCT05154370
Drug: Intravenous steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study does not limit treatment methods. Patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. Immunomodulatory therapies are necessary for the remission stage. All drugs are used in accordance with relevant guidelines.
Trial: NCT04705844
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (4 SC injections of equal volume administered at separate sites on the thigh or abdomen)
Trial: NCT05001763
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose, 2mg, tablet.
Trial: NCT06703463
Drug: MK-1167
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via oral capsule per dosing regimen.
Trial: NCT05667415
Drug: disulfiram and cisplatin
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: on the first day of treatment, patients were given intravenous drip of 80mg/m2 cisplatin, and 21 days was a course of treatment, lasting for 6 courses. Take 400mg disulfiram orally every day, and continue to use it until the end of chemotherapy. According to the patient's tolerance to disulfiram, the dose of disulfiram can be re-evaluated during the treatment, and the lowest dose is 125mg per day. The clinical symptoms, signs and adverse reactions of patients were observed, and the treatment effect of patients was evaluated after two consecutive cycles with 3 weeks as a cycle.
Trial: NCT05672394
Drug: lidocaine with epinephrine
RxNorm normalized name: epinephrine / lidocaine Cartridge [Xylocaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ccs of 1.5% lidocaine with 1:200,000 epinephrine
Trial: NCT05154968
Drug: Citrate buffer
RxNorm normalized name: Citrate Buffer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC infusion.
Trial: NCT05876832
Drug: XY0206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form:Tablet;Multiple dose phase:Take the medicine once a day,37.5mg at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until the subjects meet the withdrawal criteria.
Trial: NCT05350371
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo tablets will be an exact replica of the pirfenidone tablet.
Trial: NCT05984784
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo Intravenous Infusion
Trial: NCT05053139
Drug: NNC0365-3769 (Mim8)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mim8 will be injected into a skinfold on the stomach with a thin needle either once a week or once a month.
Trial: NCT05206877
Drug: Insulin, 4 units
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical insulin 100 U/ml, 1 drop per day
Trial: NCT05206877
Drug: Insulin, 20 units
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical insulin 500 U/ml, 1 drop per day
Trial: NCT05206877
Drug: insulin, 4 units twice daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop of low dose insulin twice daily.
Trial: NCT05206877
Drug: insulin, 20 units twice daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop of high dose insulin twice daily
Trial: NCT05206877
Drug: insulin, 4 units three times daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop of low dose insulin three times daily.
Trial: NCT05206877
Drug: insulin, 20 units three times daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop of high dose insulin three times daily.
Trial: NCT05593549
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcrystalline cellulose will be given at a dose of 10g mixed in 500 mL of water to be consumed 1 time per day for 14 days
Trial: NCT06406153
Drug: Antipyretic
RxNorm normalized name: ANTIPYRETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An antipyretic is administered one hour before the infusion.
Trial: NCT05707741
Drug: dexmetomedine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml mixture of saline 49 ml and dexmedetomidine 100 μg,
Trial: NCT05707741
Drug: Dexmetomedine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml mixture of saline 48 ml and dexmedetomidine 200 μg
Trial: NCT06563895
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-active control administered orally twice daily (BID)
Trial: NCT02043821
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 14days
Trial: NCT05134727
Drug: AZD5055
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy participants will receive AZD5055
Trial: NCT05134727
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy participants will receive placebo
Trial: NCT05634447
Drug: Drug: CKD-391, QD, PO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: CKD-331, D337 QD, PO
Trial: NCT06638671
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will consume metformin or placebo in a randomized order. Participants will complete exercise visits during each treatment phase.
Trial: NCT05606913
Drug: IBI362
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI362 administered subcutaneously (SC) once a week.
Trial: NCT05896254
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT06153251
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT06523465
Drug: Simvastatin combined with Amlodipine besylate
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-month treatment of Simvastatin combined with Amlodipine besylate
Trial: NCT06523465
Drug: Simvastatin combined with Spironolactone and Amlodipine besylate.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month treatment of Simvastatin combined with Spironolactone and Amlodipine besylate.
Trial: NCT06523465
Drug: Amlodipine besylate combined Spironolactone
RxNorm normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-month treatment of Amlodipine besylate combined with Spironolactone
Trial: NCT05548543
Drug: HCP2202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once per period.
Trial: NCT05548543
Drug: RLD2202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once per period.
Trial: NCT05548543
Drug: RLD2203
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once per period.
Trial: NCT05675072
Drug: FB2001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FB2001 for Inhalation will be reconstituted with normal saline prior to nebulized inhalation. FB2001 will be administered by nebulized inhalation.
Trial: NCT05675072
Drug: FB2001 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FB2001 placebo will be reconstituted with normal saline prior to nebulized inhalation. FB2001 placebo will be administered by nebulized inhalation.
Trial: NCT06233058
Drug: Drospirenone+ Ethinyl Estradiol Tablets-Test product
RxNorm normalized name: drospirenone / ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Manufactured by: Umeda Company Limited, Thailand
Trial: NCT06233058
Drug: Drospirenone+ Ethinyl Estradiol Tablets-Reference product
RxNorm normalized name: drospirenone / ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Manufactured by: Bayer AG, Berlin, Germany
Trial: NCT05130671
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care treatment as per the hospital guidelines